MBCL-46. TREATMENT OF RECURRENT WINGLESS-ACTIVATED MEDULLOBLASTOMA (Wnt-MB) INCORPORATING MARROW-ABLATIVE THIOTEPA AND CARBOPLATIN CHEMOTHERAPY (HDCx) AND AUTOLOGOUS HEMATOPOIETIC PROGENITOR CELL RESCUE (AuHPCR): A DUAL REPORT
Micah Harris(University of Pittsburgh Medical Center), Mohamed S Abdelbaki(Nationwide Children's Hospital), Jeremy Jones(Nationwide Children's Hospital), Zachary Funk(Nationwide Children's Hospital), Daniel R. Boué(Nationwide Children's Hospital), Rolla Abu‐Arja(Nationwide Children's Hospital), Jonathan L. Finlay(The Ohio State University), Margaret Shatara(Nationwide Children's Hospital), Stephan Paul(West Virginia University Hospitals), Jeffery J. Auletta(Nationwide Children's Hospital), Christopher R. Pierson(Nationwide Children's Hospital), Jeffrey R. Leonard(Universität Hamburg), Diana S. Osorio(Nationwide Children's Hospital)
Cited by 0
Related Papers
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554
Subgroup-Specific Prognostic Implications of <i>TP53</i> Mutation in Medulloblastoma
|Journal of Clinical Oncology|2013|488
Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
|Nature Communications|2019|372
Gray matter injury associated with periventricular leukomalacia in the premature infant
|Acta Neuropathologica|2007|315
Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors
|Proceedings of the National Academy of Sciences|2008|261